Skip to main content
Livermore
Livermore
ZHEN

Apexigen, Inc.

APGNDelisted Aug 23, 2023
Industry
Pharmaceutical Preparations
SEC CIK
0001814140

Apexigen, Inc. was delisted on Aug 23, 2023; its insiders filed their last Form 4 on Aug 25, 2023; 17 institutions reported holding it in 13F filings for Q2 2023, worth $1.37M in total; no superinvestor held it.

Holders of 5% or more of APGN

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Apexigen, Inc., largest stake first. The change is against the holder's previous filing.

No holder currently reports owning 5% or more of Apexigen, Inc. on Schedule 13D or 13G.

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

5 Schedule 13D and 13G filings on Apexigen, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on APGN
Filed (ET)FilerFormStakeChangeEvent dateFiling
Feb 13, 2023Periscope Capital Inc.13G/AOld format–––SEC
Feb 13, 2023Yang Xiaodong13GOld format–New–SEC
Jan 26, 2023Kepos Capital LP13G/AOld format–––SEC
Aug 11, 20223E Bioventures Capital, L.P.13GOld format–New–SEC
Aug 8, 2022Decheng Capital China Life Sciences USD Fund II, L.P.13GOld format–New–SEC
Aug 1, 2022Feis Lawrence13G/AOld format–––SEC
Apr 13, 2022Feis Lawrence13GOld format–New–SEC
Feb 14, 2022Periscope Capital Inc.13GOld format–New–SEC
Feb 4, 2022Kepos Capital LP13GOld format–New–SEC
Mar 10, 2021Glazer Capital, LLC13G/AOld format–––SEC
Feb 12, 2021Brookline Capital Holdings LLC13DOld format–New–SEC
Feb 10, 2021Glazer Capital, LLC13GOld format–New–SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Apexigen, Inc. shares.

No Form 144 notices for Apexigen, Inc. are on file.